FDA approves drug for treatment-resistant metastatic colorectal cancer

The FDA has approved the use of tucatinib — a drug engineered by biotech company Seagen — in tandem with trastuzumab as a second-line treatment for colorectal cancer that has not responded to other therapies.

Read the full post at Becker's ASC
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive